| Schedule of financial information by reportable segment |
The following is financial information relating to the Company's reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
Nine Months Ended |
|
|
March 31, |
|
March 31, |
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
Net sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Protein Sciences |
|
$ |
218,903 |
|
$ |
213,176 |
|
$ |
622,739 |
|
$ |
615,332 |
Diagnostics and Genomics |
|
|
75,669 |
|
|
77,679 |
|
|
213,577 |
|
|
203,191 |
Intersegment |
|
|
(426) |
|
|
(479) |
|
|
(934) |
|
|
(1,152) |
Consolidated net sales |
|
$ |
294,146 |
|
$ |
290,376 |
|
$ |
835,382 |
|
$ |
817,371 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
Protein Sciences |
|
$ |
98,756 |
|
$ |
96,750 |
|
$ |
274,035 |
|
$ |
280,131 |
Diagnostics and Genomics |
|
|
11,464 |
|
|
19,405 |
|
|
28,399 |
|
|
37,748 |
Segment operating income |
|
$ |
110,220 |
|
$ |
116,155 |
|
$ |
302,434 |
|
$ |
317,879 |
Costs recognized on sale of acquired inventory |
|
|
— |
|
|
— |
|
|
(400) |
|
|
(1,596) |
Amortization of acquisition related intangible assets |
|
|
(19,286) |
|
|
(18,173) |
|
|
(57,694) |
|
|
(54,942) |
Impact of partially-owned consolidated subsidiaries(1) |
|
|
— |
|
|
(892) |
|
|
647 |
|
|
(3,446) |
Acquisition related expenses and other |
|
|
1,333 |
|
|
3,710 |
|
|
9,343 |
|
|
19,328 |
Eminence impairment |
|
|
— |
|
|
— |
|
|
— |
|
|
(18,715) |
Stock based compensation, inclusive of employer taxes |
|
|
(10,543) |
|
|
(9,056) |
|
|
(42,879) |
|
|
(37,731) |
Restructuring costs |
|
|
— |
|
|
291 |
|
|
(2,950) |
|
|
(1,638) |
Corporate general, selling, and administrative expenses |
|
|
(1,513) |
|
|
(1,588) |
|
|
(4,082) |
|
|
(3,122) |
Consolidated operating income |
|
$ |
80,211 |
|
$ |
90,447 |
|
$ |
204,419 |
|
$ |
216,017 |
(1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023.
|